Tests multi-CAR-T cell therapy in hard-to-treat B cell lymphomas
Tests modified T cells against B cell lymphoma that resisted other treatments.
Plain-language title generated from the registry record
Registry title: Multi-CAR-T Cells Targeting B Cell Lymphomas
Key facts
- Where
- Shenzhen, ChinaSee the site
- Phase
- Phase 1/2
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Trial code
- NCT04429438
- Record updated
- 2 November 2026
- Original description
This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CARTs as booster and consolidation treatment for patients with highly resistant B cell lymphomas, including primary mediastinal B cell lymphoma (PMBCL) and BCL involving central nervous system (CNS-BCL). Clinical response and development of a simplified and standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.Read full original descriptionShow less
Primary, Booster and Consolidation Multi-CAR-T Cell Therapy for the Treatment of Refractory B Cell Lymphomas
This study aims to evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting B cell surface molecules including CD19 and alternative CARTs as booster and consolidation treatment for patients with highly resistant B cell lymphomas, including primary mediastinal B cell lymphoma (PMBCL) and BCL involving central nervous system (CNS-BCL). Clinical response and development of a simplified and standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Inclusion: Age older than 6 months; Primary B cell lymphoma surface expression of CD19 and/or CD22/CD70/PSMA/ CD13/CD79b/GD2 molecules; The KPS score over 80 points, and survival time is more than 1 month; Greater than Hgb 80 g/L; No contraindications to blood cell collection.
Exclusion: Pregnant and nursing mothers.6. under systemic steroid treatment within a week of the treatment; Prior failed CAR-T treatment; Accompanied with other active diseases, and difficult to assess response after treatment; Bacterial, fungal, or viral infection, unable to control; Living with HIV; Active HBV and HCV infection.